BioTuesdays

Category - Markets

Synthetic Biologics Logo
Markets

HCW starts Synthetic Biologics at buy; PT $1

H.C. Wainwright initiated coverage of Synthetic Biologics (NYSE AMERICAN:SYN) with a “buy” rating and price target of $1. The stock finished at 25 cents on May 17. Analyst Edward White writes that the new coverage is...

May 21, 2018
Agile Therapeutics
Markets

HCW halves Agile Therapeutics PT to $4

H.C. Wainwright halved its price target for Agile Therapeutics (NASDAQ:AGRX) to $4 from $8 after the company updated the regulatory status of Twirla, its weekly transdermal contraceptive patch. The stock closed at 69...

May 21, 2018
Helius Medical Technologies Logo
Markets

BTIG starts Helius Medical at buy; PT $14

BTIG initiated coverage of Helius Medical Technologies (NASDAQ:HSDT) with a “buy” rating and $14 price target. The stock closed at $11.11 on May 16. “Helius has the potential to help people with traumatic brain injuries...

May 17, 2018
Anavex
Markets

Maxim ups Anavex Life Sciences PT to $7

Maxim Group raised its price target for Anavex Life Sciences (NASDAQ:AVXL) to $7 from $5, after factoring in Anavex 2-73 for additional indications: Rett syndrome and Parkinson’s disease, beyond Alzheimer’s disease. The...

May 16, 2018
Markets

Roth starts Daré Bioscience at buy; PT $6

Roth Capital Partners initiated coverage of Daré Bioscience (NASDAQ:DARE) with a “buy” rating and $6 price target. The stock closed at $1.07 on May 15. Daré brings innovation to the contraception market, writes analyst...

May 16, 2018
Sophiris Bio Logo
Markets

Maxim ups Sophiris Bio PT to $8

Maxim Group raised its price target for Sophiris Bio (NASDAQ:SPHS) to $8 from $5, factoring in topsalysin data in prostate cancer at the end of the second quarter. The stock was quoted at $3.55 in afternoon trading on...

May 15, 2018
Zymeworks Logo
Markets

Ladenburg starts Zymeworks at buy; PT $25

Ladenburg Thalmann initiated coverage of Zymeworks (NYSE:ZYME) with a “buy” rating and $25 price target. The stock closed at $15.84 on May 14. Zymeworks is developing bispecific/multifunctional biotherapeutics initially...

May 15, 2018
Coherus BioSciences Logo
Markets

Maxim ups Coherus Biosciences PT to $22

Maxim Group raised its price target for Coherus Biosciences (NASDAQ:CHRS) to $22 from $18 after the FDA has accepted for review the recently resubmitted BLA for CHS-1701 (Neulasta biosimilar). This is a Type I response...

May 14, 2018
Tandem Diabetes Care
Markets

Piper ups Tandem Diabetes to OW; PT $13

Piper Jaffray upgraded Tandem Diabetes (NASDAQ:TNDM) to “overweight” from “neutral” and raised its price target to $13 from $8 after hosting meetings with the company’s CEO and CFO. The stock closed at $8.90 on April 11...

May 14, 2018